Inovio Pharmaceuticals, Inc. (INO) stock
INONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.63+0.23 (+16.43%)
Close on Nov 17, 2026Market cap $168.54MP/E –Yield –
Inovio Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Inovio Pharmaceuticals's total assets was $49.39M at Jun 30, 2026. For fiscal 2025 it was $74.31M, down 34.4% from the year before. Over ten years it grew -10.0% a year on average. The highest annual figure on record is $539.77M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.31M | -34.4% |
| FY2024 | Dec 31, 2024 | $113.20M | -33.8% |
| FY2023 | Dec 31, 2023 | $170.95M | -51.0% |
| FY2022 | Dec 31, 2022 | $348.53M | -29.7% |
| FY2021 | Dec 31, 2021 | $495.94M | -8.1% |
| FY2020 | Dec 31, 2020 | $539.77M | +275.0% |
| FY2019 | Dec 31, 2019 | $143.95M | +9.8% |
| FY2018 | Dec 31, 2018 | $131.11M | -30.0% |
| FY2017 | Dec 31, 2017 | $187.24M | +7.8% |
| FY2016 | Dec 31, 2016 | $173.71M | -18.8% |
| FY2015 | Dec 31, 2015 | $213.84M | +62.3% |
| FY2014 | Dec 31, 2014 | $131.79M | +49.3% |
| FY2013 | Dec 31, 2013 | $88.29M | +95.6% |
| FY2012 | Dec 31, 2012 | $45.14M | -26.1% |
| FY2011 | Dec 31, 2011 | $61.11M | +9.0% |
| FY2010 | Dec 31, 2010 | $56.07M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $49.39M | -27.6% |
| Q1 FY2026 | Mar 31, 2026 | $49.78M | -43.0% |
| Q4 FY2025 | Dec 31, 2025 | $74.31M | -34.4% |
| Q3 FY2025 | Sep 30, 2025 | $69.39M | -35.2% |
| Q2 FY2025 | Jun 30, 2025 | $68.24M | -49.0% |
| Q1 FY2025 | Mar 31, 2025 | $87.27M | -32.4% |
| Q4 FY2024 | Dec 31, 2024 | $113.20M | -33.8% |
| Q3 FY2024 | Sep 30, 2024 | $107.06M | -44.6% |
| Q2 FY2024 | Jun 30, 2024 | $133.80M | -42.6% |
| Q1 FY2024 | Mar 31, 2024 | $129.11M | -51.6% |
| Q4 FY2023 | Dec 31, 2023 | $170.95M | -51.0% |
| Q3 FY2023 | Sep 30, 2023 | $193.10M | -50.7% |
| Q2 FY2023 | Jun 30, 2023 | $233.04M | -49.3% |
| Q1 FY2023 | Mar 31, 2023 | $266.58M | -40.2% |
| Q4 FY2022 | Dec 31, 2022 | $348.53M | -29.7% |
| Q3 FY2022 | Sep 30, 2022 | $391.97M | -26.8% |
| Q2 FY2022 | Jun 30, 2022 | $459.40M | -22.4% |
| Q1 FY2022 | Mar 31, 2022 | $445.51M | -32.0% |
| Q4 FY2021 | Dec 31, 2021 | $495.94M | -8.1% |
| Q3 FY2021 | Sep 30, 2021 | $535.76M | +22.4% |
| Q2 FY2021 | Jun 30, 2021 | $591.84M | +33.5% |
| Q1 FY2021 | Mar 31, 2021 | $654.86M | +93.2% |
| Q4 FY2020 | Dec 31, 2020 | $539.77M | +275.0% |
| Q3 FY2020 | Sep 30, 2020 | $437.81M | +188.9% |
| Q2 FY2020 | Jun 30, 2020 | $443.19M | +168.5% |
| Q1 FY2020 | Mar 31, 2020 | $338.92M | +77.3% |
| Q4 FY2019 | Dec 31, 2019 | $143.95M | +9.8% |
| Q3 FY2019 | Sep 30, 2019 | $151.53M | +7.7% |
| Q2 FY2019 | Jun 30, 2019 | $165.07M | +10.8% |
| Q1 FY2019 | Mar 31, 2019 | $191.17M | +10.1% |
| Q4 FY2018 | Dec 31, 2018 | $131.11M | -30.0% |
| Q3 FY2018 | Sep 30, 2018 | $140.70M | -30.9% |
| Q2 FY2018 | Jun 30, 2018 | $148.92M | -6.3% |
| Q1 FY2018 | Mar 31, 2018 | $173.66M | +13.3% |
| Q4 FY2017 | Dec 31, 2017 | $187.24M | +7.8% |
| Q3 FY2017 | Sep 30, 2017 | $203.68M | +4.7% |
| Q2 FY2017 | Jun 30, 2017 | $158.85M | – |
| Q1 FY2017 | Mar 31, 2017 | $153.31M | – |
| Q4 FY2016 | Dec 31, 2016 | $173.71M | – |
| Q3 FY2016 | Sep 30, 2016 | $194.55M | – |
See a number that looks wrong?